Latest news
Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 15:00:00 GMTMerck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline - Business WireBusiness Wire · Tue, 04 Aug 2026 10:30:00 GMTBarclays Adjusts Merck & Co. Price Target to $150 From $140, Maintains Overweight Rating - MoomooMoomoo · Tue, 28 Jul 2026 12:36:36 GMT